SCHEMBL4575224

SCHEMBL4575224

NC(F)C(F)CF

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29118921 1.00
Hydrochloric Acid SCHEMBL14331833 0.96
Hydrochloric Acid SCHEMBL28904836 0.74
SCHEMBL18666201 0.74
SCHEMBL1470791 0.74
SCHEMBL3674582 0.72
SCHEMBL3045165 0.70
SCHEMBL8463482 0.69
SCHEMBL14862507 0.69
SCHEMBL21174017 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116410106-A Benzamide HBV capsid protein inhibitor and preparation method and application thereof 潍坊医学院 2023-07-11 CN claimed
WO-2024104441-A1 SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2024-05-23 WO disclosed
CN-114524810-B Pyrimidine heterocyclic compounds, preparation method and application 上海凌达生物医药有限公司 2023-12-01 CN disclosed
CN-116410106-A Benzamide HBV capsid protein inhibitor and preparation method and application thereof 潍坊医学院 2023-07-11 CN disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
EP-4146645-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO Pharmaceutical Co., Ltd. (JP) 2023-03-15 EP disclosed
EP-3980010-A1 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS Arcus Biosciences, Inc. (US) 2022-04-13 EP disclosed
WO-2021223699-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2021-11-11 WO disclosed
CN-112969692-A Bumetanide derivatives for the treatment of hyperhidrosis 兹伦汀公司 2021-06-15 CN disclosed
EP-3790865-A1 PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT Janssen Pharmaceutica NV (BE) 2021-03-17 EP disclosed
WO-2015134171-A1 HETEROARYLAMIDE INHIBITORS OF TBK1 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-11 WO disclosed
WO-2015118057-A1 SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UC (IE) 2015-08-13 WO disclosed
WO-2015057659-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 WO disclosed
EP-2771337-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH Novartis AG (CH) 2014-09-03 EP disclosed
CN-103797010-A Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE CORP 2014-05-14 CN disclosed
EP-2646446-A2 BROMODOMAIN INHIBITORS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2013-10-09 EP disclosed
WO-2013046136-A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH NOVARTIS AG (CH) 2013-04-04 WO disclosed
WO-2012075383-A2 BROMODOMAIN INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2012-06-07 WO disclosed
WO-2008060845-A2 RADIOLABELED VITAMIN B12 AND ITS DERIVATIVES USEFUL FOR POSITRON EMISSION TOMOGRAPHY IMAGING NAVISCAN PET SYSTEMS, INC. (US) 2008-05-22 WO disclosed